Table 1 Clinical characteristics of patients included in the survival genome-wide association study.
Characteristic | BelCovid (n = 381) | GENCOVID (n = 1727) | Hostage (n = 1303) | SPGRX (n = 364) | SweCovid (n = 129) | Total (n = 3904) |
|---|---|---|---|---|---|---|
Age at diagnosis, years, median (range) | 59 (23–104) | 60 (18–99) | 65 (1–96) | 71 (23–103) | 61 (24–86) | 63 (1–104) |
Age at diagnosis, years, n (%) | ||||||
< 55 | 151 (39.6) | 615 (35.6) | 318 (24.4) | 66 (18.1) | 42 (32.6) | 1192 (30.5) |
55–64 | 89 (23.4) | 416 (24.1) | 321 (24.6) | 59 (16.2) | 31 (24.0) | 916 (23.5) |
65–74 | 83 (21.8) | 345 (20.0) | 363 (27.9) | 88 (24.2) | 30 (23.3) | 909 (23.3) |
75–84 | 43 (11.3) | 227 (13.1) | 202 (15.5) | 88 (24.2) | 24 (18.6) | 584 (15.0) |
> 85 | 15 (3.94) | 124 (7.18) | 99 (7.60) | 63 (17.3) | 2 (1.55) | 303 (7.76) |
Sex, n (%) | ||||||
Male | 199 (52.2) | 1032 (59.8) | 773 (59.3) | 188 (51.6) | 91 (70.5) | 2283 (58.5) |
Female | 182 (47.8) | 695 (40.2) | 530 (40.7) | 176 (48.4) | 38 (29.5) | 1621 (41.5) |
Infection before June 30th, 2020, n (%) | ||||||
No | 41 (10.8) | 1075 (62.2) | 118 (9.06) | 0 | 17 (13.2) | 1251 (32.0) |
Yes | 340 (89.2) | 652 (37.8) | 1185 (90.9) | 364 (100) | 112 (86.8) | 2653 (68.0) |
Hospitalization, n (%) | ||||||
No | 125 (32.8) | 357 (20.7) | 9 (0.691) | 52 (14.3) | 0 | 543 (13.9) |
Yes | 256 (67.2) | 1370 (79.3) | 1294 (99.3) | 312 (85.7) | 129 (100) | 3361 (86.1) |
ICU admission, n (%) | ||||||
No | 238 (62.5) | 1566 (90.7) | 961 (73.8) | 263 (72.2) | 0 | 3028 (77.6) |
Yes | 143 (37.5) | 161 (9.32) | 342 (26.2) | 101 (27.7) | 129 (100) | 876 (22.4) |
Highest respiratory support, n (%) | ||||||
None | 0 | 605 (35.0) | 0 | 0 | 0 | 605 (15.5) |
Oxygen (mask or cannula) | 124 (32.5) | 592 (34.3) | 854 (65.5) | 0 | 0 | 1570 (40.2) |
Non-invasive ventilation * | 6 (1.57) | 369 (21.4) | 63 (4.83) | 0 | 0 | 438 (11.2) |
Intubation | 103 (27.0) | 161 (9.32) | 298 (22.9) | 0 | 0 | 562 (14.4) |
Not available | 148 (38.8) | 0 | 88 (6.75) | 364 (100) | 129 (100) | 729 (18.7) |
Number of comorbidities, n (%) | ||||||
None | 64 (16.8) | 865 (50.1) | 323 (24.8) | 0 | 36 (27.9) | 1322 (33.9) |
1 | 97 (25.5) | 522 (30.2) | 305 (23.4) | 0 | 48 (37.2) | 964 (24.7) |
2 | 72 (18.9) | 205 (11.9) | 174 (13.4) | 0 | 36 (27.9) | 469 (12.0) |
3 or more | 22 (5.77) | 55 (3.18) | 54 (4.14) | 0 | 9 (6.98) | 132 (3.38) |
Not available | 126 (33.1) | 80 (4.63) | 447 (34.3) | 364 (100) | 0 | 1013 (26.1) |
Comorbidity, n (%) | ||||||
Asthma | 34 (8.92) | 148 (8.57) | 91 (6.98) | 22 (17.1) | 295 (7.56) | |
Cancer | 51 (13.4) | 126 (7.30) | 154 (11.8) | 15 (11.6) | 346 (8.86) | |
Diabetes | 89 (23.4) | 207 (12.0) | 266 (20.4) | 35 (27.1) | 597 (15.3) | |
Heart failure | 39 (10.2) | 160 (9.26) | 87 (6.68) | 6 (4.65) | 292 (7.48) | |
Hypertension | 156 (40.9) | 484 (28.0) | 554 (42.5) | 70 (54.3) | 1264 (32.4) | |
Alive status (at 60 days of follow-up), n (%) | ||||||
Alive | 335 (87.9) | 1622 (93.9) | 1147 (88.0) | 286 (78.6) | 95 (73.6) | 3485 (89.3) |
Deceased | 46 (12.1) | 105 (6.08) | 156 (12.0) | 78 (21.4) | 34 (26.4) | 419 (10.7) |
Series, n (%) | ||||||
BelCovid | 381 (9.76) | |||||
GEN-COVID | 1727 (44.2) | |||||
Hostage | 1303 (33.4) | |||||
SPRGX | 364 (9.32) | |||||
SweCovid | 129 (3.33) | |||||
